<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895777</url>
  </required_header>
  <id_info>
    <org_study_id>1160.106</org_study_id>
    <secondary_id>2013-002114-12</secondary_id>
    <nct_id>NCT01895777</nct_id>
  </id_info>
  <brief_title>Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)</brief_title>
  <official_title>Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica</authority>
    <authority>Austria: Medicines and Medical Devices Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal and Health Products</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Agence Nationale sécurité médicament et des produits santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority
      study of dabigatran etexilate versus standard of care in children from birth to less than 18
      years of age will assess the efficacy and safety of dabigatran relative to low molecular
      weight heparins or vitamin K antagonists for treatment of VTE. This study will also assess
      the appropriateness of the proposed dabigatran doses for use in paediatric patients using
      three different formulations of dabigatran (capsules, pellets and oral liquid formulation)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>First component of the co-primary endpoint: A combined efficacy endpoint of complete thrombus resolution plus freedom from recurrent VTE plus freedom from mortality related to VTE</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Second component of the co-primary endpoint: Freedom from major bleeding events (a safety endpoint)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments (plasma concentrations of total dabigatran) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment</measure>
    <time_frame>3, 7, 21, 42, 63 and 84 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of dose adjustments</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of switch of type of anti-coagulation therapy (including dabigatran to SOC) and a switch from an intended standard of care treatment to another</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from thrombus progression at baseline and at days 21 and 84 after randomisation</measure>
    <time_frame>3 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the acceptability of an age-appropriate formulation at end of therapy</measure>
    <time_frame>3 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from recurrence of VTE at 6, 9 and 12 months</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from occurrence of post-thrombotic syndrome at 6, 9 and 12 months</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All bleeding events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All components of the primary efficacy endpoints</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessments (aPTT, ecarin clotting time (ECT) and dTT) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment</measure>
    <time_frame>3, 7, 21, 42, 63 and 84 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of  temporary discontinuation from therapy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of  permanent discontinuation from therapy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of laboratory monitoring requirements for dose adjustment during the treatment phase</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low molecular weight heparin or vitamin K antagonist prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation</description>
    <arm_group_label>dabigatran etexilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>Low molecular weight heparin or vitamin K antagonist prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)</description>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female subjects 0 to less than 18 years of age at the time of informed
             consent / assent

          -  Documented diagnosis of VTE per investigator judgment initially treated (generally
             5-7 days) with an unfractionated heparin (UFH) or a low molecular weight heparin
             (LMWH).

          -  Clinical indication for 3 month of treatment with anticoagulants for the VTE episode
             defined under the above inclusion criterion.

          -  Written informed consent provided by the patient's parent or legal guardian and
             assent provided by the patient (if applicable) at the time of informed consent form
             (ICF) signature according to local regulations.

        Exclusion criteria:

          -  Conditions associated with an increased risk of bleeding

          -  Renal dysfunction (eGFR &lt; 80 mL/min/1.73m2 using the Schwartz formula) or requirement
             for dialysis

          -  Active infective endocarditis

          -  Subjects with a mechanical or a biological heart valve prosthesis

          -  Hepatic disease:

        Active liver disease, including known hepatitis A, B or C or, Persistent alanine
        aminotransferase (ALT) or aspartate transaminase (AST) or alkaline phosphatase (AP) &gt; 3 ×
        upper limit of normal (ULN) within 3 months of screening

          -  Pregnant or breast feeding females. Females who have reached menarche and are not
             using a medically accepted contraceptive method per local guidelines. Acceptable
             methods of birth control may include: Intra Uterine Device (IUD); oral, implantable
             or injectable contraceptives and estrogen patch; double barrier method (spermicide +
             diaphragm); or abstinence at the discretion of the investigator

          -  Anemia (hemoglobin &lt; 80g/L) or thrombocytopenia (platelet count &lt; 80 x 109/L) at
             screening. Transfusions during the screening period are allowed, provided that a
             satisfactory hemoglobin or platelet level is attained prior to visit 2

          -  Patients who have taken prohibited or restricted medication within one week of the
             first dose of study medication other than medication for prior VTE treatment.

          -  Patients who have received an investigational drug in the past 30 days prior to
             screening

          -  Patients who are allergic/sensitive to any component of the study medication
             including solvent

          -  Patients or parents/legal guardians considered unreliable to participate in the trial
             per investigator judgment or any condition which would present a safety hazard to the
             patient based on investigator judgment

          -  Patients or parents/legal guardians who are unwilling or unable to undergo or permit
             repeat of the baseline imaging tests required to confirm thrombus resolution at study
             days 21 and 84 or in whom repeating such imaging tests at these pre-specified time
             points may not be medically in the patient's best interest. Examples may include
             unwarranted radiation exposure as a result of a repeat CT scan at study day 21 and
             day 84 for a patient with an isolated case of pulmonary embolism evaluated at
             baseline solely by a CT scan. In such cases, the baseline radiological assessment
             (e.g. CT) may be supplemented with an acceptable non-radiological assessment at
             baseline (e.g. MRI) which could then be repeated at day 21 and day 84 hence
             alleviating any potential unwarranted radiation exposure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1160.106.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middelheim</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.97201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.97202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nuevo León</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.106.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
